Contrasting mechanisms of action and sensitivity to antipsychotics of phencyclidine versus amphetamine: Importance of nucleus accumbens 5-HT2A sites for PCP-induced locomotion in the rat

European Journal of Neuroscience

Volumn 11, Issue 12, 1999, Pages 4419-4432

  Millan, M J ^a   Brocco, M ^a   Gobert, A ^a   Joly, F ^a   Bervoets, K ^a   Rivet, J M ^a   Newman Tancredi, A ^a   Audinot, V ^a   Maurel, S ^a  

^a INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

Author keywords

Antipsychotics; Clozapine; Nucleus accumbens; Phencyclidine; Schizophrenia

Indexed keywords

ALPHA (2,3 DIMETHOXYPHENYL) 1 [2 (4 FLUOROPHENYL)ETHYL] 4 PIPERIDINEMETHANOL; AMISULPRIDE; AMPHETAMINE; EPLIVANSERIN; ETICLOPRIDE; FANANSERIN; OXIDOPAMINE; PHENCYCLIDINE; RACLOPRIDE; RITANSERIN; SEROTONIN 2A RECEPTOR;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DRUG MECHANISM; FRONTAL CORTEX; LOCOMOTION; MALE; NONHUMAN; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; RAT;

AMPHETAMINE; ANIMALS; ANTIPSYCHOTIC AGENTS; AREA UNDER CURVE; BINDING, COMPETITIVE; CORPUS STRIATUM; DOPAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ANTAGONISM; FRONTAL LOBE; LOCOMOTION; MALE; MICRODIALYSIS; MOTOR ACTIVITY; NUCLEUS ACCUMBENS; PHENCYCLIDINE; RATS; RATS, WISTAR; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTORS, DOPAMINE D2; RECEPTORS, SEROTONIN; SEROTONIN;

EID: 0033452114     PISSN: 0953816X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1460-9568.1999.00858.x     Document Type: Article

References (103)

1. Abraham, H.D., Aldridge, A.M. & Gogia, P. (1996) The psychopharmacology of hallucinogens. Neuropsychopharmacology, 14, 285-298.
2. Adams, B. & Moghaddam, B. (1998) Corticolimbic dopamine neurotransmission is temporally dissociated from the cognitive and locomotor effects of phencyclidine. J. Neurosci., 15, 5545-5554.
3. Akbarian, S., Sucher, N.J., Bradley, D., Tafazzoli, A., Trinh, D., Hetrick, W.P., Potkin, S.G., Sandman, C.A., Bunney, W.E. & Jones, E.G. (1996) Selective alterations in gene expression for N-methyl-D-aspartate receptor subunits in prefrontal cortex of schizophrenics. J. Neurosci., 16, 19-30.
4. Andreasen, N.C., Rezai, K., Alliger, R., Swayze, V.W., Flaum, M., Kirchner, P., Cohen, G. & O'Leary, D. (1992) Hypofrontality in neuroleptic-naive patients and in patients with chronic schizophrenia. Arch. Gen. Psychiatry, 49, 943-958.
5. Arora, R.C. & Meltzer, H.Y. (1980) In vitro effect of phencyclidine and other psychomotor stimulants on serotonin uptake in human platelets. Life Sci., 27, 1607-1613.
6. 2) receptor binding in the frontal cortex of schizophrenic patients. J. Neural Transm., 85, 19-29.
7. Bakshi, V.P., Swerdlow, N.R. & Geyer, M.A. (1994) Clozapine antagonizes phencyclidine-induced deficits in sensorimotor gating of the startle response. J. Pharmacol. Exp. Ther., 271, 787-794.
8. Brunello, N., Masotto, C., Staeardo, L., Markstein, R. & Racagni, G. (1995) New insights into the biology of schizophrenia through the mechanism of action of clozapine. Neuropsychopharmacology, 13, 177-213.
9. 2A receptor mRNAs and binding site densities are differentially altered in schizophrenia. Neuropsychopharmacology, 15, 442-445.
10. Busatto, G.F. & Kerwin, R.W. (1997) Perspectives of the role of serotonergic mechanisms in the pharmacology of schizophrenia. J. Psychopharmacol., 11, 3-12.
11. 2A receptor antagonist MDL 100,907 counteracts the psychomotor stimulation ensuing manipulations with monoaminergic, glutaminergic or muscarinic neurotransmission in the mouse-implications for psychosis. J. Neural Transm., 100, 225-237.
12. Ceci, A. & French, E.D. (1998) Effects of phencyclidine on ventral tegmental A10 dopamine neurons in rats with lesions of the prefrontal cortex, accumbens and dorsal raphe nuclei. Ann. NY Acad. Sci., 537, 500-501.
13. Chen, A.C.H., McDonald, B., Moss, S.J. & Gurling, H.M.D. (1998) Gene expression of the mRNAs encoding the N-methyl-D-aspartate receptor subunits NMDAR1, NMDAR2A, NMDAR2B, NMDAR2C, and NMDAR2D following long-term treatment with cis- and trans-flupenthixol as a model for understanding the mode of action of schizophrenia drug treatment. Mol. Brain Res., 54, 92-100.
14. Corbett, R. (1995) Clozapine but not haloperidol antagonizes an MK-801 discriminative stimulus cue. Pharmacol. Biochem. Behav., 51, 561-564.
15. Dalia, A., Uretsky, N.J. & Wallace, L.J. (1998) Dopaminergic agonists administered into the nucleus accumbens: effects on extracellular glutamate and on locomotor activity. Brain Res., 788, 111-117.
16. Deutch, A.Y., Tan, S.Y., Freeman, A.S., Bowers, B.B. & Roth, R.H. (1987) Mesolimbic and mesocortical dopamine activation induced by phencyclidine contrasting pattern to striatal response. Eur. J. Pharmacol., 134, 257-264.
17. Duncan, G.E., Leipzig, J.N., Mailman, R.B. & Lieberman, J.A. (1998) Differential effects of clozapine and haloperidol on ketamine-induced brain metabolic action. Brain Res., 812, 65-75.
18. Fleming, K., Bigelow, L.B., Weinberger, D.R. & Goldberg, T.E. (1995) Neuropsychological effects of amphetamine may correlate with personality characteristics. Psychopharmacol. Bull., 31, 357-362.
19. French, E.D., Ferkany, J., Abreu, M. & Levenson, S. (1991) Effects of competitive N-methyl-D-aspartate antagonist on midbrain dopamine neurons: an electrophysiological and behavioral comparison to phencyclidine. Neuropharmacology, 30, 1039-1046.
20. Gattaz, W.F., Schummer, B. & Berhens, S. (1994) Effects of zotepine, haloperidol and clozapine on MK-801-induced stereotypy and locomotion in rats. J. Neural Transm., 96, 227-232.
21. Gleason, M.M. & Shannon, H.E. (1997) Blockade of phencyclidine-induced hyperlocomotion by olanzapine, clozapine and serotonin receptor subtype selective antagonist in mice. Psychopharmacology, 129, 79-84.
22. Glennon, R.A. (1988) Site-selective serotonin agonists as discriminative stimuli. Psychopharmacology, 4, 16-31.
23. 1A receptor agonists and antagonists: a comparison to adrenergic and dopaminergic neurones in individual rats. J. Pharmacol. Exp. Ther., 273, 1032-1046.
24. Gobert, A., Rivet, J.-M., Maurel-Rémy, S., Cistarelli, C. & Millan, M.J. (1995b) Modulation of dopamine (DA), noradrenaline (NAD) and serotonin (5-HT) release in frontal cortex, accumbens and striatum of freely-moving rats by psychostimulant drugs. Soc. Neurosci. Abstr., 21, 1108.
25. Gobert, A., Rivet, J.-M., Audinot, V., Newman-Tancredi, A., Cistarelli, L. & Millan, M.J. (1998) Simultaneous quantification of serotonin, dopamine and noradrenaline levels in single frontal cortex dialysates of freely-moving rats reveals a complex pattern of reciprocal auto- and heteroreceptor-mediated control of release. Neuroscience, 84, 413-429.
26. Gorelick, D.A., Balster, R.L. (1995) Phencyclidine (PCP). In Bloom, F.E. & Kupfer, D.J. (eds), Psychopharmacology: The Fourth Generation of Progress. Raven Press, New York, pp. 1767-1776.
27. Gurevich, E.V. & Joyce, J.N. (1997) Alterations in the cortical serotonergic system in schizophrenia: a postmortem study. Biol. Psychiatry, 54, 225-232.
28. Hernandez, L., Auerbach, S. & Hoebel, B.G. (1988) Phencyclidine (PCP) injected in the nucleus accumbens increases extracellular dopamine and serotonin as measured by microdialysis. Life Sci., 42, 1713-1723.
29. Hiramatsu, M., Cho, A.K. & Nabeshisma, T. (1989) Comparison of the behavioral and biochemical effects of the NMDA receptor antagonists, MK-801 and phencyclidine. Eur. J. Pharmacol., 166, 359-366.
30. Hori, T., Suzuki, T., Baba, A., Abe, S., Yamamoto, T., Moroji, T. & Shiraishi, H. (1996) Effects of phencyclidine metabolites on serotonin uptake in rat brain. Neurosci. Lett., 209, 153-156.
31. Javitt, D.C. & Zukin, S.R. (1991) Recent advances in the phencyclidine model of schizophrenia. Am. J. Psychiatry, 148, 1301-1308.
32. Jentsch, J.D., Dazzi, L., Chhatwal, J.-P., Verrico, C.D. & Roth, R.H. (1998a) Reduced prefrontal cortical dopamine, but not acetylcholine, release in vivo after repeated, intermittent phencyclidine administration to rats. Neurosci. Lett., 258, 175-178.
33. Jentsch, J.D., Taylor, J.R. & Roth, R.H. (1998b) Subchronic phencyclidine administration increases mesolimbic dopaminergic system responsivity and augments stress- and psychostimulant-induced hyperlocomotion. Neuropsychopharmacology, 19, 105-113.
34. Kehne, J.H., Sant, W.S. & Sorenson, C.A. (1981) The effects of radio-frequency lesions of the nucleus accumbens on D-amphetamine-induced locomotor and rearing behavior in rats. Psychopharmacology, 75, 363-367.
35. 2A antagonist with a favorable CNS safety profile. J. Pharmacol. Exp. Ther., 277, 968-981.
36. 2 receptor-mediated behavior, head-twitch response, in mice. Life Sci., 63, 2305-2311.
37. Kinon, B.J. & Lieberman, J.A. (1996) Mechanisms of action of atypical antipsychotic drugs: a critical analysis. Psychopharmacology, 124, 2-34.
38. Knable, M.B. & Weinberger, D.R. (1997) Dopamine, the prefrontal cortex and schizophrenia. J. Psychopharmacol., 11, 123-131.
39. 1A receptors. Eur. J. Pharmacol., 260, 79-83.
40. 3 dopamine receptor: neurobiology and potential clinical relevance. Pharmacol. Rev., 49, 231-252.
41. Lidsky, T.I., Alter, E. & Banerjee, S.P. (1996) Contribution of glutamatergic dysfunction to schizophrenia. Drug News Persp., 9, 453-459.
42. Lillrank, S.M., O'Connor, W.T., Oja, S.S. & Ungerstedt, U. (1994) Systemic phencyclidine administration is associated with increased dopamine, GABA, and 5-HIAA levels in the dorsolateral striatum of conscious rats: an in vivo microdialysis study. J. Neural Transm., 95, 145-155.
43. Löschner, W. & Hönack, D. (1992) The behavioural effects of MK-801 in rats: involvement of dopaminergic, serotonergic and noradrenergic systems. Eur. J. Pharmacol., 215, 199-208.
44. Maj, J., Rogóz, Z., Skuza, G. & Wedzony, K. (1996) The synergistic effect of fluoxetine on the locomotor hyperactivity induced by MK-801, a noncompetitive NMDA receptor antagonist. J. Neural Transm., 103, 131-146.
45. Maldonado-Irizarry, C. & Kelley, A.E. (1994) Differential behavioral effects following microinjection of an NMDA antagonist into nucleus accumbens subregions. Psychopharmacology, 116, 65-72.
46. Martin, P., Svensson, A., Carlsson, A. & Carlsson, M.L. (1994) On the roles of dopamine D-1 vs D-2 receptors for the hyperactivity response elicited by MK-801. J. Neural Transm., 95, 113-121.
47. Martin, J.R., Berman, M.H., Krewsun, I. & Small, S.F. (1979) Phencyclidine-induced stereotyped behavior and serotoninergic syndrome in rat. Life Sci., 24, 1699-1704.
48. Martin, P., Carlsson, M.L. & Hjorth, S. (1998a) Systemic PCP treatment elevates brain extracellular 5-HT: a microdialysis study in awake rats. Neuroreport, 9, 2985-2988.
49. Martin, P., Waters, N., Carlsson, A. & Carlsson, M.L. (1997) MK-801-induced hyperlocomotion: differential effects of M100907, SDZ PSD 958 and raclopride. Eur. J. Pharmacol., 335, 107-116.
50. 2A receptor antagonism is dependent on increased serotonergic tone. J. Neural Transm., 105, 365-396.
51. 2A receptors. Br. J. Pharmacol., 114, 154P.
52. 2A receptors. Eur. J. Pharmacol., 280, R9-R11.
53. 2A receptors in the nucleus accumbens. Soc. Neurosci. Abstr., 24, 1741.
54. 2 agonists and antagonists. Brain Res., 562, 216-224.
55. McCullough, L.D. & Salamone, J.D. (1992) Increase in extracellular dopamine levels and locomotor activity after direct infusion of phencyclidine into nucleus accumbens. Brain Res., 577, 1-9.
56. Meltzer, H.Y. (1995) Atypical antipsychotic drugs. In Bloom, F.E. & Kupfer, D.J. (eds), Psychopharmacology: The Fourth Generation of Progress. Raven Press, New York, pp. 1277-1286.
57. Meltzer, L.T., Christoffersen, C.L. & Serpa, K.A. (1997) Modulation of dopamine neuronal activity by glutamate receptor subtypes. Neurosci. Biobehav. Rev., 21, 511-518.
58. Miczek, K.A. & Yoshimura, H. (1982) Disruption of primate social behaviour by d-amphetamine and cocaine: differential antagonism by antipsychotics. Psychopharmacology, 76, 163-171.
59. Middlemiss, D.N. & Tricklebank, M.D. (1992) Centrally active 5-HT receptor agonists and antagonists. Neurosci. Biobehav. Rev., 16, 75-82.
60. Millan, M.J. & Seguin, L. (1994) Chemically-diverse ligands at the glycine B site coupled to N-methyl-D-aspartate (NMDA) receptors selectively block the late phase of formalin-induced pain in mice. Neurosci. Lett., 178, 139-143.
61. 2 receptors elicits prolactin secretion and catalepsy. J. Pharmacol. Exp. Ther., 275, 885-898.
62. 1A agonist properties: I. Receptorial and neurochemical profile in comparison with clozapine and haloperidol. J. Pharmacol. Exp. Ther., 286, 1341-1355.
63. 1A agonist properties: II. Functional profile in comparison to clozapine and haloperidol. J. Pharmacol. Exp. Ther., 286, 1356-1373.
64. Millan, M.J., Newman-Tancredi, A., Brocco, M., Gobert, A., Lejeune, F., Audinot, V., Rivet, J.-M., Schreiber, R., Dekeyne, A., Speeding, M., Nicolas, J.-P. & Péglion, J.-L. (1998c) S 18126 ({2-[4-(2,3-dihydrobenzo[1,4] dioxin-6-yl) piperazin-1-yl methyl] indan-2-yl}), a potent, selective and competitive antagonist at dopamine D4 receptors: an in vitro and in vivo comparison with L 745,870 (3-(4-[4-chlorophenyl] piperaein-1-yl) methyl-1H-pyrrolo [2,3b] pyridine) and raclopride. J. Pharmacol. Exp. Ther., 287, 167-186.
65. Morari, M., Marti, M., Sbrenna, S., Fuxe, K., Bianchi, C. & Beani, L. (1998) Reciprocal dopamine-glutamate modulation of release in the basal ganglia. Neurochem. Int., 33, 383-397.
66. 2A receptor antagonist MDL 100,907 attenuates the behavioural and neurochemical effects of PCP in rodents. Br. J. Pharmacol., 123, 241P.
67. Nabeshima, T.K., Yamada, K., Yamaguchi, H., Hiramatsu, M., Furukawa, H. & Kameyama, T. (1983) Effect of lesions in the striatum, nucleus accumbens and medial raphe on phencyclidine-induced stereotyped behaviors and hyperactivity in rats. Eur. J. Pharmacol., 91, 455-462.
68. Nabeshima, T.K., Ishikawa, K., Yamaguchi, H., Furukawa, H. & Kameyama, T. (1987) Phencyclidine-induced head-weaving observed in mice after ritanserin treatment. Eur. J. Pharmacol., 139, 171-178.
69. 2 receptors by sulfhydryl-modifying reagents. Biochem. Pharmacol., 37, 3277-3283.
70. 4.4 receptors: actions of antiparkinsonian and antipsychotic agents. J. Pharmacol. Exp. Ther., 282, 181-191.
71. 2A receptor antagonists block MK-801-induced stereotypy and hyperlocomotion. Eur. J. Pharmacol., 358, 111-116.
72. Nowak, G., Legutko, B., Skolnick, P. & Popik, P. (1998) Adaptation of cortical NMDA receptors by chronic treatment with specific serotonin reuptake inhibitors. Eur. J. Pharmacol., 342, 367-370.
73. O'Neill, K.A., Carelli, R.M., Jarvis, M.F. & Liebman, J.M. (1989) Hyperactivity induced by N-methyl-D-aspartate injection into nucleus accumbens: lack of evidence for mediation by dopaminergic neurons. Pharmacol. Biochem. Behav., 34, 739-745.
74. O'Neill, M.F., Hicks, C.A., Shaw, G., Parameswaran, T., Cardwell, G.P. & O'Neill, M.J. (1998) Effects of 5-hydroxytryptamine2 receptor antagonism on the behavioral activation and immediate early gene expression induced by dizocilpine. J. Pharmacol. Exp. Ther., 287, 839-846.
75. Ögren, S.O. & Goldstein, M. (1994) Phencyclidine- and dizocilpine-induced hyperlocomotion are differentially mediated. Neuropsychopharmacology, 11, 167-177.
76. 2A antagonist for treatment of schizophrenia: early indication of safety and clinical activity in schizophrenic patients. CINP meeting, Glasgow, Scotland, 1998.
77. Olney, J.W. & Farber, N.B. (1995) Glutamate receptor dysfunction and schizophrenia. Arch. Gen. Psychiatry, 52, 998-1007.
78. 2 receptor blockade on MK-801-induced hyperlocomotion in rats. Psychopharmacology, 5, 427-434.
79. 1A autoreceptors. Brain Res., 783, 173-178.
80. 3 dopamine receptor antagonist activity and limbic selectivity. J. Pharmacol. Exp. Ther., 280, 73-82.
81. Pickar, D. (1995) Prospects for pharmacotherapy of schizophrenia. Lancet, 345, 557-562.
82. Plaznik, A., Jessa, M. & Nazar, M. (1997) The behavioural effects of N-methyl-D-aspartate antagonists in serotonin depleted rats. Pharmacol. Biochem. Behav., 58, 159-166.
83. Ridley, R.M., Baker, H.F. & Haystead, T.A. (1981) Perseverative behaviour after amphetamine: dissociation of response tendency from reward association. Psychopharmacology, 75, 283-286.
84. 2 receptor antagonist. J. Pharmacol. Exp. Ther., 262, 759-768.
85. Roth, B.L. & Meltzer, H.Y. (1995) The role of serotonin in schizophrenia. In Bloom, F.E. & Kupfer, D.J. (eds), Psychopharmacology: The Fourth Generation of Progress. Raven Press, New York, pp. 1215-1228.
86. Rothman, R.B., Reid, A.A., Monn, J.A., Jacobson, A.E. & Rice, K.C. (1989) The psychomimetic drug phencyclidine labels two high affinity binding sites in guinea pig brain: evidence for N-methyl-D-aspartate-coupled and dopamine reuptake carrier-associated phencyclidine binding sites. Mol. Pharmacol., 36, 887-896.
87. Sams-Dodd, F. (1998) A test of the predictive validity of animal models of schizophrenia based on phencyclidine and D- amphetamine. Neuropsychopharmacology, 18, 293-304.
88. 2A receptors in antipsychotic activity. Life Sci., 56, 2209-2222.
89. 1A agonists. J. Pharmacol. Exp. Ther., 273, 101-112.
90. 4 receptors. Neuropsychopharmacology, 16, 93-135.
91. Sokoloff, B.P. (1998) Expression of NMDAR1, GluR1, GluR7, and KA1 glutamate receptor mRNAs is decreased in frontal cortex of 'neuroleptic-free' schizophrenics: evidence on reversible up-regulation by typical neuroleptics. J. Neurochem., 71, 2454-2464.
92. Steinpreis, R.E. (1996) The behavioural and neurochemical effects of phencyclidine in humans and animals: some implications for modeling psychosis. Behav. Brain Res., 74, 45-55.
93. Steinpreis, R.E. & Salamone, J.D. (1993) The role of nucleus accumbens dopamine in the neurochemical and behavioral effects of phencyclidine: a microdialysis and behavioral study. Brain Res., 612, 263-270.
94. Svensson, A., Carlsson, M. & Carlsson, A. (1992) Interaction between glutamatergic and dopaminergic tone in the nucleus accumbens of mice: evidence for a dual glutamergic function with respect to psychomotor control. J. Neural Transm., 88, 235-240.
95. Swerdlow, N.R., Bakshi, V., Waikar, M., Taaid, N. & Geyer, M.A. (1998) Seroquel, clozapine and chlorpromazine restore sensomotor gating in ketamine-treated rats. Psychopharmacology, 140, 75-80.
96. Tao, R. & Auerbach, S.B. (1996) Differential effect of NMDA on extracellular serotonin in rat midbrain raphe and forebrain sites. J. Neurochem., 66, 1067-1075.
97. 2 receptor antagonist ketanserin. Eur. J. Pharmacol., 287, 201-205.
98. Wadenberg, M.L. (1996) Serotoninergic mechanisms in neuroleptic-induced catalepsy in the rat. Neurosci. Biobehav. Rev., 20, 325-339.
99. Whitton, P.S., Richards, D.A., Biggs, C. & Fowler, L.J. (1994) N-methyl-D-aspartate receptors modulate extracellular 5-hydroxytryptamine concentration in rat hippocampus and striatum in vivo. Neurosci. Lett., 169, 215-218.
100. Willins, D.L., Narayanan, S., Wallace, L.J. & Uretsky, N. (1993) The role of dopamine and AMPA/kainate receptors in the nucleus accumbens in the hypermotility response to MK801. Pharmacol. Biochem. Behav., 46, 881-887.
101. Xu, J. & Domino, E.F. (1994) Asymmetric cross-sensitization to the locomotor stimulant effects of phencyclidine and MK801. Neurochem. Int., 25, 155-159.
102. Yan, Q.S., Reith, M.E.A., Jobe, P.C. & Dailey, J.W. (1997) Dizocilpine (MK-801) increases not only dopamine but also serotonin and norepinephrine transmissions in the nucleus accumbens as measured by microdialysis in freely moving rats. Brain Res., 765, 149-158.
103. Yoneda, Y., Ogita, K. & Suzuki, T. (1990) Interaction of strychnine-insensitive glycine binding with MK-801 binding in brain synaptic membranes. J. Neurochem., 55, 237-244.